share_log

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Anson Funds Management LP(4.9%),Anson Management GP LLC(4.9%), etc.

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Anson Funds Management LP(4.9%),Anson Management GP LLC(4.9%), etc.

SC 13G/A：超過5%持股股東披露文件(修正)-Anson Funds Management LP(4.9%),Anson Management GP LLC(4.9%)等
美股SEC公告 ·  2024/11/14 18:06

Moomoo AI 已提取核心訊息

An amendment to Schedule 13G has been filed with the SEC by Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, indicating a change in their holdings of ZyVersa Therapeutics, Inc. common stock. The filing, dated September 30, 2024, reports that these entities and individuals collectively own 54,054 shares, representing 4.9% of the company's issued common stock. This stake is held by a private fund for which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors, with the power to direct voting and disposition of the shares. The amendment restates the previously filed Schedule 13G and provides updated information on the beneficial ownership, including the address and organizational details of the reporting persons. The filing also certifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of ZyVersa Therapeutics, Inc.
An amendment to Schedule 13G has been filed with the SEC by Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, indicating a change in their holdings of ZyVersa Therapeutics, Inc. common stock. The filing, dated September 30, 2024, reports that these entities and individuals collectively own 54,054 shares, representing 4.9% of the company's issued common stock. This stake is held by a private fund for which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors, with the power to direct voting and disposition of the shares. The amendment restates the previously filed Schedule 13G and provides updated information on the beneficial ownership, including the address and organizational details of the reporting persons. The filing also certifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of ZyVersa Therapeutics, Inc.
Anson Funds Management LP、Anson Management GP LLC、Tony Moore、Anson Advisors Inc.、Amin Nathoo 和 Moez Kassam 向美國證券交易委員會提交了一份對附表13G的修正案，表示他們在ZyVersa Therapeutics, Inc.普通股的持股發生變化。該文件日期爲2024年9月30日，報告這些實體和個人共持有54,054股，佔公司已發行普通股的4.9%。此股份由一傢俬募基金持有，Anson Funds Management LP 和 Anson Advisors Inc.作爲共同投資顧問，擁有投票和處置股份的權力。修正案重述了先前提交的附表13G，並提供了關於權益所有權的更新信息，包括報告人的地址和組織詳情。該文件還證明這些股份是在正常業務過程中獲得的，而不是爲了改變或影響ZyVersa Therapeutics, Inc.的控制權。
Anson Funds Management LP、Anson Management GP LLC、Tony Moore、Anson Advisors Inc.、Amin Nathoo 和 Moez Kassam 向美國證券交易委員會提交了一份對附表13G的修正案，表示他們在ZyVersa Therapeutics, Inc.普通股的持股發生變化。該文件日期爲2024年9月30日，報告這些實體和個人共持有54,054股，佔公司已發行普通股的4.9%。此股份由一傢俬募基金持有，Anson Funds Management LP 和 Anson Advisors Inc.作爲共同投資顧問，擁有投票和處置股份的權力。修正案重述了先前提交的附表13G，並提供了關於權益所有權的更新信息，包括報告人的地址和組織詳情。該文件還證明這些股份是在正常業務過程中獲得的，而不是爲了改變或影響ZyVersa Therapeutics, Inc.的控制權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間